CytomX Therapeutics's three largest insider shareholders as of March 23, 2026 are Sean A. Mccarthy (Ceo, 1.20Mn shares), Marcia Belvin (Svp, Chief Scientific Officer, 332.25K shares), Christopher Ogden (Chief Financial Officer, 316.27K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sean A. Mccarthy | Ceo | 1,078,922 | 0 | 19 Mar, 2026 |
| Marcia Belvin | Svp, Chief Scientific Officer | 300,760 | 0 | 19 Mar, 2026 |
| Christopher Ogden | Chief Financial Officer | 296,948 | 0 | 19 Mar, 2026 |
| Yu-Waye Chu | Chief Medical Officer | 189,446 | 0 | 19 Mar, 2026 |
| Lloyd A Rowland | General Counsel | 120,594 | 0 | 20 Mar, 2025 |
| Jeffrey B Landau | Chief Business Officer | 119,056 | 0 | 22 Aug, 2024 |
| Sean A. Mccarthy | President And Ceo | 0 | 93,118 | 21 Jun, 2021 |
| Amy C. Peterson | Evp, Chief Development Officer | 58,433 | 0 | 20 Mar, 2023 |
| Alison L. Hannah | Chief Medical Officer | 31,898 | 0 | 21 Jul, 2022 |
| Rachael Lester | Chief Business Officer | 20,000 | 0 | 04 Feb, 2026 |
| Elaine V Jones | 5,142 | 0 | 31 Mar, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Mar, 2026 | Christopher Ogden | Common Stock | D | 19,323 | $6.42 | 296,948 | D | S |
| 17 Mar, 2026 | Sean A. Mccarthy | Common Stock | D | 118,969 | $6.42 | 1,078,922 | D | S |
| 17 Mar, 2026 | Yu-Waye Chu | Common Stock | D | 21,279 | $6.42 | 189,446 | D | S |
| 17 Mar, 2026 | Marcia Belvin | Common Stock | D | 31,492 | $6.42 | 300,760 | D | S |
| 02 Feb, 2026 | Yu-Waye Chu | Common Stock | A | 75,000 | $0.00 | 210,725 | D | A |
| 02 Feb, 2026 | Marcia Belvin | Common Stock | A | 60,000 | $0.00 | 332,252 | D | A |
| 02 Feb, 2026 | Rachael Lester | Common Stock | A | 20,000 | $0.00 | 20,000 | D | A |
| 02 Feb, 2026 | Sean A. Mccarthy | Common Stock | A | 210,000 | $0.00 | 1,197,891 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Common Stock | A | 90,000 | $0.00 | 316,271 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Stock Option (Right to Buy) | A | 325,000 | $0.00 | 325,000 | D | A |
| 02 Feb, 2026 | Yu-Waye Chu | Stock Option (Right to Buy) | A | 300,000 | $0.00 | 300,000 | D | A |
| 02 Feb, 2026 | Marcia Belvin | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 02 Feb, 2026 | Rachael Lester | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 02 Feb, 2026 | Sean A. Mccarthy | Stock Option (Right to Buy) | A | 980,000 | $0.00 | 980,000 | D | A |
| 02 Feb, 2026 | Rachael Lester | Performance Stock Units (PSUs) | A | 50,000 | $0.00 | 50,000 | D | A |
| 06 Nov, 2025 | Sean A. Mccarthy | Class A Common Stock | D | 101,793 | $4.54 | 987,891 | D | S |
| 20 Oct, 2025 | Rachael Lester | Stock Option (Right to Buy) | A | 650,000 | $0.00 | 650,000 | D | A |
| 26 Sep, 2025 | Marcia Belvin | Stock Option (Right to Buy) | A | 36,300 | $0.00 | 36,300 | D | A |
| 26 Sep, 2025 | Sean A. Mccarthy | Stock Option (Right to Buy) | A | 570,000 | $0.00 | 570,000 | D | A |
| 26 Sep, 2025 | Christopher Ogden | Stock Option (Right to Buy) | A | 78,250 | $0.00 | 78,250 | D | A |